Joseph E. Gilliam

“Well, first, let me say it's nice to start one of these conferences and talk about corneal health first. I think it's a nice shift for us and for investors. No, obviously, you referenced the second quarter results.”

“You know, as both you and Tom alluded, we obviously are very pleased with the strong second quarter, and, you know, really each of our franchises exceeded expectations and and so as a result we were we were happy to be able to raise guidance in the line of what you heard tom mentioned earlier to the 680 to 700 million…”

“I think as it relates to the coverage and continued access to or gaining access for epioxide to the patients, I think like everything else, that's a process where there's education at the payer level around the benefits associated with this therapy and the real cost associated with the continued progression of the…”